Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Cadila Healthcare — Investor Presentation (February 2010)
22 slides from Zydus Lifesciences's investor presentation, February 2010
Slide 1: Cadila Healthcare Ltd. Investor Presentation
Cadila Healthcare Ltd. Investor Presentation February 2010 1
Slide 2: Our Vision
Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020… 2
Slide 3: A Snapshot
A Snapshot § One of the oldest and the 5th largest in the Indian formulations market worth over Rs. 370 bn (Source : ORG IMS MAT Dec-09) § Operations in US, Europe, Japan, Latin America, Asia Pacific, Africa, Middle East and CIS regions § International sales in generic markets contribute to over 33%
Slide 4: Core business areas and Revenue break-up (Apr-Dec 09)
Core business areas and Revenue break-up (Apr-Dec 09) Revenue break-up by segment ▲8% ▲36% ▲10% ▲13% ▲51% Revenue break-up by region ▲10% ▲14% ▲60% 4
Slide 5: State of the art facilities and infrastructure (1/2)
State of the art facilities and infrastructure (1/2) Formulations Finished Dosage Form, Finished Dosage Form, Finished Dosage Form, Moraiya (USFDA Approved) Sikkim Baddi Finished Dosage Form, Finished Dosage Form, Biologics, Changodar Goa Brazil Cytotoxic Injectables Cytotoxic Injectable Agiolax (fo
Slide 6: State of the art facilities and infrastructure (2/2)
State of the art facilities and infrastructure (2/2) APIs and Fine Chemicals API, Ankleshwar API, Dabhasa (USFDA Approved) (USFDA approved) Fine Chemicals, Moraiya Pantoprazole Intermediates (USFDA Approved) for Nycomed JV 6
Slide 7: Financial highlights
Financial highlights # Net Profit and EPS excludes Exceptional Items 7
Slide 8: 5th largest in Indian Pharma market with ~Rs 14 bn sales
5th largest in Indian Pharma market with ~ Rs 14 bn sales § Leading positions in key segments – CVS, GI, Female Healthcare and Respiratory Therapeutic Area-wise Sales Break-up of (participated market segments) Branded Formulations (FY 08-09) § 15 brands feature amongst the top 300 brands § New produ
Slide 9: International formulations: two-fold focus
International formulations : two-fold focus Focusing on developed generic Driving growth in emerging markets markets which constitute 28% of which contribute to 10% of global sales global sales ü US - Zydus Pharmaceuticals USA Inc. ü Brazil – ü Europe • Branded - Quimica e Pharmaceutica Nikkho Do Br
Slide 10: One of the fastest growing generic companies in US
One of the fastest growing generic companies in US Gross Sales § Started operations in 2005 and adopted a “Customer Centric Model” § 29 products launched. 8 -10 products to be added every year § Products enjoy 5 - 25% market share § Focusing on delivery based, difficult to make products, the next gr
Slide 11: Over 2.5% market share in participated French market; 27 product launches in Spain
Over 2.5 % market share in participated French market; 27 product launches in Spain Strong presence in Euro 2.3 bn French market Gross Sales § Rated one of the fastest growing companies in France by IMS § Launched >150 presentations (~75 molecules) in France § Continuous focus on enrichment of custo
Slide 12: Strategies for world's 2nd largest market valued at $3bn: Japan
Strategies for world’s 2nd largest market valued at $3bn : Japan § Market valued at $ 3 bn, growing at ~12%, with very low generic penetration of ~5% in value terms, 17% in volume terms (Source : IGPA) § Acquired Nippon Universal Pharma. Ltd. (NUP) with a marketing set-up and a small manufacturing f
Slide 13: Achievements in the $12bn Brazilian pharma market
Achievements in the $ 12bn Brazilian pharma market growing at 15-18% p.a. Gross Sales § Set up Zydus Healthcare Brazil Ltda (100% subsidiary) to enter generics market in 2005-06 § Filed 52 dossiers so far for generic and branded products from India, of which 20 have been approved. Launched 17 generi
Slide 14: Exports to emerging markets grew by >30% in last 4 years
Exports to emerging markets grew by >30% in last 4 years Gross Sales § Operations in over 20 semi / non regulated emerging markets of Asia Pacific, Africa, Middle East and CIS regions § Focusing on rapidly growing markets of Russia, South Africa, Taiwan and Philippines § No.1 Indian company in Ugand
Slide 15: Zydus Wellness – A market leader with iconic and niche consumer brands
Zydus Wellness – A market leader with iconic and niche consumer brands Restructured consumer business with de-merger of consumer business from Cadila Healthcare into Carnation in FY 08-09. Company now renamed as Zydus Wellness Ltd. 15
Slide 16: A pioneer in the low calorie sweetener segment and a trendsetter in skincare products
A pioneer in the low calorie sweetener segment and a trendsetter in skincare products § Sugar Free – India’s largest selling sugar substitute with market share of over 80% (Source : AC Nielsen). § Growing at CAGR of 25% for last 3 years, the brand recorded sales of Rs. 778 Mio. in FY 08-09 § Everyut
Slide 17: Unlocking value through win-win alliances
Unlocking value through win-win alliances § Zydus Nycomed JV – most successful contract manufacturing JV in India § State-of-the-art API mfg. plant for Pantoprazole intermediates § Expanded scope - more APIs to be sourced by Nycomed from this JV § Zydus Hospira - JV for oncology injectables (Generic
Slide 18: Ongoing Investment in Newer Portfolios Worth over $180 bn
Ongoing Investment in Newer Portfolios Worth over $ 180 bn Zydus New Portfolio Mid term Zydus New Portfolio • Biogenerics: 40 bn Near term • Transdermal: 10 bn • Vaccine: 22 bn Oral • Pulmonary: 20 bn • Topical: 16 bn • Transdermal: 10 bn • One of the leading player • Injectables: 17 bn in regulator
Slide 19: A scientific talent pool of >850 and investing over 6% of turnover on research
A scientific talent pool of >850 and investing over 6% of the turnover on research Talent Pool of ~850 Scientists Zydus Research Centre (ZRC) § Located in Ahmedabad Generics/ Developmental § Focus on NME Research, 335 scientists Biologicals & NDDS Pharmaceutical Technology Centre NME & Drug (PTC) Di
Slide 20: Dedicated facility for NME research: Zydus Research Centre
Dedicated facility for NME research : Zydus Research Centre § Areas of focus: Dyslipidemia, Diabetes, Obesity, Inflammation § Facility for target identification to pre-clinical research / early clinical development § 2nd company in India to be accredited by AAALAC (Association for Assessment and Acc
Slide 21: Highlights: Apr-Dec 09 Results
Highlights : Apr-Dec 09 Results Rs. Mio. Consolidated Growth Apr-Dec 09 Apr-Dec 08 y-y% Domestic Sales 14,562 12,735 14.3% Exports Sales 13,321 9,334 42.7% Total Gross Sales 27,883 22,069 26.3% Total Operating Income 28,403 22,041 28.9% EBIDT 6,193 4,567 35.6% EBIDT % to Total Income 21.9% 20.7% Net
Slide 22: Safe Harbour Statement
Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also disclaims a
Cadila Healthcare — Investor Presentation (February 2010) on 6ix